Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Cellular LanthaScreen and beta-lactamase reporter assays for high-throughput screening of JAK2 inhibitors.

Robers MB, Machleidt T, Carlson CB, Bi K.

Assay Drug Dev Technol. 2008 Aug;6(4):519-29. doi: 10.1089/adt.2008.144.

PMID:
18694336
2.

Comparison of two homogeneous cell-based kinase assays for JAK2 V617F: SureFire pSTAT5 and GeneBLAzer fluorescence resonance energy transfer assays.

Qian J, Mason JL, Holskin BP, Murray KA, Meyer SL, Ator MA, Angeles TS.

Assay Drug Dev Technol. 2012 Apr;10(2):212-7. doi: 10.1089/adt.2011.0399. Epub 2011 Dec 1.

PMID:
22132729
3.

Desensitization of the growth hormone-induced Janus kinase 2 (Jak 2)/signal transducer and activator of transcription 5 (Stat5)-signaling pathway requires protein synthesis and phospholipase C.

Fernández L, Flores-Morales A, Lahuna O, Sliva D, Norstedt G, Haldosén LA, Mode A, Gustafsson JA.

Endocrinology. 1998 Apr;139(4):1815-24.

PMID:
9528967
4.

Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.

Yu V, Pistillo J, Archibeque I, Han Lee J, Sun BC, Schenkel LB, Geuns-Meyer S, Liu L, Emkey R.

Exp Hematol. 2013 May;41(5):491-500. doi: 10.1016/j.exphem.2013.01.005. Epub 2013 Jan 19.

PMID:
23340136
6.

Modification of CellSensor irf1-bla TF-1 and irf1-bla HEL assays for direct comparison of wild-type JAK2 and JAK2 V617F inhibition.

Mason JL, Holskin BP, Murray KA, Meyer SL, Wells-Knecht KJ, Ator MA, Angeles TS.

Assay Drug Dev Technol. 2011 Jun;9(3):311-8. doi: 10.1089/adt.2010.0297. Epub 2010 Dec 6.

PMID:
21133674
7.

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.

Pardanani A, Hood J, Lasho T, Levine RL, Martin MB, Noronha G, Finke C, Mak CC, Mesa R, Zhu H, Soll R, Gilliland DG, Tefferi A.

Leukemia. 2007 Aug;21(8):1658-68. Epub 2007 May 31.

PMID:
17541402
8.

HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.

Menier C, Guillard C, Cassinat B, Carosella ED, Rouas-Freiss N.

Leukemia. 2008 Mar;22(3):578-84. Epub 2007 Dec 6.

PMID:
18059484
9.

An inhibitor of Janus kinase 2 prevents polycythemia in mice.

Mathur A, Mo JR, Kraus M, O'Hare E, Sinclair P, Young J, Zhao S, Wang Y, Kopinja J, Qu X, Reilly J, Walker D, Xu L, Aleksandrowicz D, Marshall G, Scott ML, Kohl NE, Bachman E.

Biochem Pharmacol. 2009 Aug 15;78(4):382-9. doi: 10.1016/j.bcp.2009.04.025. Epub 2009 May 3.

PMID:
19413997
10.

Imatinib effect on growth and signal transduction in polycythemia vera.

Gaikwad A, Verstovsek S, Yoon D, Chang KT, Manshouri T, Nussenzveig R, Cortes J, Vainchenker W, Prchal JT.

Exp Hematol. 2007 Jun;35(6):931-8.

PMID:
17533047
11.
12.

Janus kinase-signal transducer and activator of transcription mediates phosphatidic acid-induced interleukin (IL)-1beta and IL-6 production.

Lee C, Lim HK, Sakong J, Lee YS, Kim JR, Baek SH.

Mol Pharmacol. 2006 Mar;69(3):1041-7. Epub 2005 Dec 14.

13.

Jak2-Stat5 interactions analyzed in yeast.

Barahmand-Pour F, Meinke A, Groner B, Decker T.

J Biol Chem. 1998 May 15;273(20):12567-75.

14.

In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.

Ahmed KB, Warner SL, Chen A, Gourley ES, Liu X, Vankayalapati H, Nussenzveig R, Prchal JT, Bearss DJ, Parker CJ.

Exp Hematol. 2011 Jan;39(1):14-25. doi: 10.1016/j.exphem.2010.09.013. Epub 2010 Oct 8.

PMID:
20934482
15.

WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.

Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z.

Clin Cancer Res. 2008 Feb 1;14(3):788-96. doi: 10.1158/1078-0432.CCR-07-0524.

16.

mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms.

Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, Bosi A, Vannucchi AM; Associazione Italiana per la Ricerca sul Cancro AGIMM Gruppo Italiano Malattie Mieloproliferative.

PLoS One. 2013;8(1):e54826. doi: 10.1371/journal.pone.0054826. Epub 2013 Jan 31.

17.

A cell-based beta-lactamase reporter gene assay for the identification of inhibitors of hepatitis C virus replication.

Zuck P, Murray EM, Stec E, Grobler JA, Simon AJ, Strulovici B, Inglese J, Flores OA, Ferrer M.

Anal Biochem. 2004 Nov 15;334(2):344-55.

PMID:
15494142
18.

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.

Liu PC, Caulder E, Li J, Waeltz P, Margulis A, Wynn R, Becker-Pasha M, Li Y, Crowgey E, Hollis G, Haley P, Sparks RB, Combs AP, Rodgers JD, Burn TC, Vaddi K, Fridman JS.

Clin Cancer Res. 2009 Nov 15;15(22):6891-900. doi: 10.1158/1078-0432.CCR-09-1298. Epub 2009 Nov 3.

19.

Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.

Boissinot M, Cleyrat C, Vilaine M, Jacques Y, Corre I, Hermouet S.

Oncogene. 2011 Feb 24;30(8):990-1001. doi: 10.1038/onc.2010.479. Epub 2010 Nov 1.

PMID:
21042281
20.

Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera.

Kraus M, Wang Y, Aleksandrowicz D, Bachman E, Szewczak AA, Walker D, Xu L, Bouthillette M, Childers KM, Dolinski B, Haidle AM, Kopinja J, Lee L, Lim J, Little KD, Ma Y, Mathur A, Mo JR, O'Hare E, Otte RD, Taoka BM, Wang W, Yin H, Zabierek AA, Zhang W, Zhao S, Zhu J, Young JR, Marshall CG.

PLoS One. 2012;7(5):e37207. doi: 10.1371/journal.pone.0037207. Epub 2012 May 18.

Supplemental Content

Support Center